Quotient Therapeutics

News

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

News

Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.